Vicarious Surgical (RBOT) Long-Term Investments (2020 - 2023)

Vicarious Surgical's (RBOT) quarterly Long-Term Investments came in at $50.0 million in Q2 2023, little changed on a QoQ basis from $49.8 million in Q1 2023.

Vicarious Surgical (RBOT) Long-Term Investments (2020 - 2023) Analysis & Trends

Vicarious Surgical (RBOT) has 3 years of Long-Term Investments data on file, last reported at $50.0 million in Q2 2023.

  • On a quarterly basis, Long-Term Investments changed N/A year-over-year to $50.0 million in Q2 2023; TTM through Jun 2023 was $50.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $345.2 million, changed N/A from the prior year.
  • Long-Term Investments for Q2 2023 stood at $50.0 million, roughly flat from $49.8 million in the prior quarter.
  • Over the last five years, Long-Term Investments for RBOT reached as high as $345.3 million in Q2 2021 and fell as low as $49.8 million in Q1 2023.
  • Historically, Long-Term Investments has averaged $246.8 million across 3 years, with a median of $345.1 million in 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 1.09 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn -
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn -
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn -
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 285.60 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 166.25 Mn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn -
9 Smith & Nephew 25.80 Bn 25.22 Bn - 121.00 Mn
10 Vicarious Surgical 654,984.55 -9.14 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 49.98 Mn
Mar 31, 2023 49.77 Mn
Jun 30, 2021 345.27 Mn
Mar 31, 2021 345.26 Mn
Dec 31, 2020 345.19 Mn
Sep 30, 2020 345.09 Mn